gMendel

gMendel is an AI-powered, vertically-integrated IVD certified technology that aims to transform the diagnosis of genetic disorders for better disease management. With over 350 million people worldwide suffering from over 10,000 genetic disorders and rare diseases, but less than 500 of these diseases having an approved treatment, there is a significant unmet clinical need for better, faster, and more affordable companion diagnostics for rare diseases. The societal burden of rare diseases exceeds €2 trillion, underscoring the urgency for precision treatments. The current diagnosis of rare diseases takes an average of 7 years, is costly, complex, and leaves many patients undiagnosed. gMendel® offers an end-to-end cloud-based technology that utilizes AI for the accurate, fast, and affordable diagnosis of multiple rare diseases and beyond. Having obtained the CE mark under EU IVDD in 2022, gMendel® is the world’s first IVD certified technology for human genetic disorders utilizing long-read sequencing technology and AI. The technology has also achieved Proof of Concept to detect deletions, insertions, and point mutations by conducting whole exome sequencing or DNA region customization. The company is currently in the process of commercializing its technology for companion diagnostics for Anemia, Epilepsy, Cystic Fibrosis, and Spinal Muscular Atrophy. gMendel®'s novel combination of genomics and AI sets it apart, making its technology better, faster, and more affordable than existing offerings in the companion diagnostics market.